The DEA marijuana hearing has entered a critical and uncertain phase. A federal appeals court and the Drug Enforcement Administration are now weighing whether cannabis should shift its legal status under American law. The outcome could reshape enforcement, taxation and regulation across the country. It has already triggered fierce opposition from public health groups, law enforcement organisations and several states.

How the DEA marijuana hearing push began

The dispute traces back to a December 2025 executive order. That order directed the Attorney General to pursue cannabis rescheduling as quickly as possible. Acting Attorney General Todd Blanche responded in April with a final order. His order immediately moved FDA approved cannabis products and state licensed medical cannabis from Schedule I to Schedule III of the Controlled Substances Act.

The ordinary route typically requires public notice, a comment period and a formal administrative hearing. Officials at the Department of Justice skipped that path entirely. They instead relied on a treaty implementation provision that lets the Attorney General bypass standard procedures when necessary to satisfy international drug control obligations. That shortcut has become the central legal flashpoint ahead of the wider marijuana rescheduling hearing now under way.

Petitioners challenge the order before the DEA marijuana hearing concludes

Three separate petitions challenging the order have since been filed and consolidated before the D.C. Circuit Court of Appeals. This sets the stage for what is likely to become the first appellate test of this rescheduling approach.

Smart Approaches to Marijuana, an anti legalisation group, filed the first petition on 4 May. It filed alongside the National Drug and Alcohol Screening Association, a drug testing trade body. Indiana and Nebraska followed with a second petition on 22 May, after Louisiana withdrew its involvement. A third petition arrived on 28 May from a coalition. That coalition includes a substance abuse treatment provider, physicians, a cannabis victims advocacy organisation and a pharmaceutical developer.

Collectively, the petitioners want the order vacated. They argue the Department of Justice violated the Administrative Procedure Act. Officials, they add, sidestepped required procedural safeguards and acted arbitrarily by skipping public input altogether. Their central claim rests on a 1977 appellate ruling. That ruling, they argue, limits the treaty provision to narrow circumstances and does not permit cannabis to sit below Schedule II without a clear treaty mandate.

The petitioners further warn that the order creates a confusing hybrid regulatory regime. It places certain cannabis products in Schedule III while keeping restrictions normally reserved for more tightly controlled substances, including production quotas and import export controls. Congress, they contend, never authorised such a blend of regulatory regimes.

Two of the petitioners asked the court on 9 June to pause the order while judicial review continues. They warned that irreversible harm could occur if implementation proceeds before the legal questions are settled. In turn, the government filed its response on 2 July. Its decision on that request is expected to be the first significant marker of how this fight will unfold.

Inside the DEA marijuana hearing

Meanwhile, the Drug Enforcement Administration is pressing ahead with its own expedited marijuana rescheduling hearing. Officials are examining whether cannabis more broadly, including for recreational use, should also move to Schedule III. That hearing opened on 29 June and is scheduled to conclude by 15 July. It follows an earlier Biden era attempt that stalled amid procedural disputes.

The current process has drawn its own criticism. On 18 June, the agency named seven participants for the hearing, and every one of them opposes rescheduling. The list includes Smart Approaches to Marijuana, the National Drug and Alcohol Screening Association, a coalition of states, the Tennessee Bureau of Investigation, the group DUID Victim Voices and two physicians. As a result, not a single organisation supporting rescheduling made the cut. Officials concluded that pro rescheduling groups had failed to show they were adversely affected by the proposed change. Requests to reconsider that decision, including one from NORML, were denied on 24 June.

Despite the one sided participant list, the DEA marijuana hearing may not be entirely predictable. The agency itself formally proposed the rule, so it must carry the burden of defending rescheduling during the proceedings. In its opening statement, the agency confirmed its support for the change. Officials said they planned to call an FDA scientist and a pain physician to testify about cannabis and its potential medical applications.

What the DEA marijuana hearing could mean next

The stakes extend well beyond legal technicalities. A stay from the D.C. Circuit could freeze the new DEA registration pathway for medical cannabis operators. It could also suspend tax relief available to Schedule III businesses under a key section of the tax code. Public health advocates and drug policy researchers are watching closely too, given longstanding concerns about how loosened classification could shift youth perception of risk and broader consumption patterns. Researchers have repeatedly flagged that shifts in legal status tend to coincide with changes in how young people view the risks of regular use, a pattern that has shaped debate around every prior rescheduling proposal.

For now, the outcome of the DEA marijuana hearing hinges on two institutions working in parallel. An appellate court must decide whether the Department of Justice had the authority to act as it did. A separate agency tribunal is compiling a record that could push cannabis policy even further. Whichever way both processes conclude, the decisions are likely to shape how cannabis is regulated, taxed and perceived across the United States for years to come.

Source: reuters